Indication · with post-anti-pd-1 advanced melanoma

with post-anti-pd-1 advanced melanoma FDA approvals, PDUFA dates and pipeline.

Updated Snapshot 20261116T222116ZBuilt

We track 1 with post-anti-pd-1 advanced melanoma drug. 1 FDA approval recorded, most recently Amtagvi® (lifileucel) on February 16, 2024.

Drugs

DrugSponsorModalityDesignations
Amtagvi® (lifileucel)IOVAcell_therapyAccelerated Approval, Breakthrough Therapy, Fast Track, Orphan Drug, Priority Review, RMAT

Upcoming catalysts

No events in this view.

Past catalysts and decisions

DateDrugCompanyEventIndicationStatusSource
February 16, 2024Amtagvi® (lifileucel)IOVAFDA approvalwith post-anti-PD-1 advanced melanomaApprovedSEC 8-K Exhibit 99.1

All indications · Approval rates by indication

Not submitted to search engines: Needs 2 drugs and 3 sourced events; has 1 and 1.

Questions

What with post-anti-pd-1 advanced melanoma drugs have upcoming PDUFA dates?

None disclosed.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.